Macrophage migration inhibitory factor and glucocorticoid sensitivity

Rheumatology

Volumn 45, Issue 8, 2006, Pages 937-943

  Aeberli, D ^a   Leech, M ^a   Morand, Eric F ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

Glucocorticoids; MIF; Rheumatoid arthritis; Steroid sparing

Indexed keywords

COLLAGENASE 3; CYCLOOXYGENASE 2; CYTOKINE RECEPTOR ANTAGONIST; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; MACROPHAGE MIGRATION INHIBITION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PARATHYROID HORMONE; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR AP 1;

ANTIINFLAMMATORY ACTIVITY; DELAYED HYPERSENSITIVITY; DRUG DOSE REGIMEN; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; UPREGULATION;

ANIMALS; ARTHRITIS, RHEUMATOID; GLUCOCORTICOIDS; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGE MIGRATION-INHIBITORY FACTORS;

EID: 33747847197     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel142     Document Type: Review

References (107)

1. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43.
2. Kirwan JR, Balint G, Szebenyi B. Anniversary: 50 years of glucocorticoid treatment in rheumatoid arthritis. Rheumatology 1999;38:100-2.
3. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003;139:359-70.
4. Ramsey-Goldman R. Missed opportunities in physician management of glucocorticoid-induced osteoporosis? Arthritis Rheum 2002;46:3115-20.
5. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study. Br Med J 1996;313:344-6.
6. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
7. Fleischmann RM, Schechtman J, Bennett R et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003;48: 927-34.
8. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action. Arthritis Rheum 2004;50:3408-17.
9. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
10. Pisu M, James N, Sampsel S, Saag KG. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology 2005;44:781-8.
11. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24:445-51.
12. del Rincon ID, Williams K, Stern MP et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
13. Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7.
14. El-Magadmi M, Bodill H, Ahmad Y et al. Systemic lupus erythematosus: An independent risk factor for endothelial dysfunction in women. Circulation 2004;110:399-404.
15. Manzi S, Selzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
16. Souverein PC, Berard A, Van Staa TP et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004;90:859-65.
17. del Rincon I, O'Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004;50:3813-22.
18. Rich AR, Lewis MR. Migration of neutrophils and macrophages. Bull John Hopkins Hosp 1932;50:115-31.
19. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966;153:80-2.
20. David JR. Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1966;56:72-7.
21. Bernhagen J, Calandra T, Mitchell RA et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993;365:756-9.
22. Mitchell R, Bacher M, Bernhagen J et al. Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). J Immunol 1995;154:3863-70.
23. Sun HW, Bernhagen J, Bucala R, Lolis E. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 1996;93:5191-6.
24. Rosengren E, Bucala R, Aman P et al. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 1996;2:143-9.
25. Calandra T, Roger T. Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 2003;3:791-800.
26. Bernhagen J, Mitchell RA, Calandra T et al. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 1994;33:14144-55.
27. Bacher M, Meinhardt A, Lan HY et al. MIF expression in the rat brain: implications for neuronal function. Mol Med 1998;4:217-30.
28. Nishio Y, Minami A, Kato H et al. Identification of macrophage migration inhibitory factor (MIF) in rat peripheral nerves: Its possible involvement in nerve regeneration. Biochem Biophys Acta 1999;1453:74-82.
29. Wada S, Fujimoto S, Mizue Y, Nishihira J. Macrophage migration inhibitory factor in the human ovary: Presence in the follicular fluids and production by granulosa cells. Biochem Mol Biol Int 1997;41:805-14.
30. Meinhardt A, Bacher M, McFarlane JR et al. Macrophage migration inhibitory factor production by Leydig cells: Evidence for a role in the regulation of testicular function. Endocrinology 1996;137:5090-5.
31. Imamura K, Nishihira J, Suzuki M et al. Identification and immunohistochemical localization of macrophage migration inhibitory factor in human kidney. Biochem Mol Biol Int 1996;40:1233-42.
32. Shimizu T, Ohkawara A, Nishihira J, Sakamoto W. Identification of macrophage migration inhibitory factor (MIF) in human skin and its immmunohistochemical localization. FEBS Lett 1996;381:199-202.
33. Wistow GJ, Shaughnessy MP, Lee DC et al. A macrophage migration inhibitory factor is expressed in the differentiating cells of the eye lens. Proc Natl Acad Sci USA 1993;90:1272-5.
34. Bozza M, Satoskar AR, Lin G et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999;189:341-6.
35. Leech M, Lacey DC, Xue JR et al. Macrophage migration inhibitory factor (MIF) regulates p53 in inflammatory arthritis. Arthritis Rheum 2003;48:1881-9.
36. Ichiyama H, Onodera S, Nishihira J et al. Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody/ lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF). Cytokine 2004;26:187-94.
37. Calandra T, Echtenacher B, Roy DL et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000;6:164-70.
38. Pan JH, Sukhova GK, Yang JT et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2004;109:3149-53.
39. de Jong YP, Abadia-Molina AC, Satoskar AR et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001;2:1061-6.
40. Mizue Y, Ghani S, Leng L et al. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci USA 2005;102:14410-5.
41. Denkinger CM, Denkinger M, Kort JJ et al. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol 2003;170:1274-82.
42. Oshima S, Onodera S, Amizuka N et al. Macrophage migration inhibitory factor-deficient mice are resistant to ovariectomy-induced bone loss. FEBS Lett 2006.
43. Ohkawara T, Miyashita K, Nishihira J et al. Transgenic overexpression of macrophage migration inhibitory factor renders mice markedly more susceptible to experimental colitis. Clin Exp Immunol 2005;140:241-8.
44. Sasaki S, Nishihira J, Ishibashi T et al. Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. Kidney Int 2004;65:469-81.
45. Leng L, Metz CN, Fang Y et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-76.
46. Firestein GS, Manning AM. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999;42:609-21.
47. Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogenactivated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999;274:18100-6.
48. Santos LL, Lacey D, Yang Y et al. Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor. J Rheumatol 2004;31:1038-43.
49. Kleemann R, Hausser A, Geiger G et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000;408:211-6.
50. Daun JM, Cannon JG. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IκBα. Am J Physiol Regul Integr Comp Physiol 2000;279R1043-9.
51. Lacey D, Sampey A, Mitchell R et al. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum 2003;48:103-9.
52. Leech M, Metz C, Hall P et al. Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 1999;42:1601-8.
53. Morand EF, Leech M, Weedon H et al. Macrophage migration inhibitory factor in rheumatoid arthritis: Clinical correlations. Rheumatology 2002;41:558-62.
54. Santos L, Hall P, Metz C et al. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: Interaction with glucocorticoids. Clin Exp Immunol 2001;123:309-14.
55. Leech M, Metz C, Santos L et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 1998;41:910-7.
56. Mikulowska A, Metz CN, Bucala R, Holmdahl R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol 1997;158:5514-7.
57. Donn RP, Shelley E, Ollier WE, Thomson W. A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001;44:1782-5.
58. Baugh JA, Chitnis S, Donnelly SC et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002;3:170-6.
59. Radstake TR, Sweep FC, Welsing P et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005;52:3020-9.
60. Chesney J, Metz C, Bacher M et al. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 1999;5:181-91.
61. Nishihira J, Koyama Y, Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine 1998;10:199-205.
62. Ogawa H, Nishihira J, Sato Y et al. An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine 2000;12:309-14.
63. Gregory JL, Leech MT, David JR et al. Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis Rheum 2004;50:3023-34.
64. Calandra T, Bernhagen J, Metz CN et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:68-71.
65. Donnelly SC, Haslett C, Reid PT et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 1997;3:320-3.
66. Bacher M, Metz CN, Calandra T et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996;93:7849-54.
67. Sampey AV, Hall PH, Mitchell RA et al. Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. Arthritis Rheum 2001;44:1273-80.
68. Onodera S, Nishihira J, Iwabuchi K et al. Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J Biol Chem 2002;277:7865-74.
69. Hudson JD, Shoaibi MA, Maestro R et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999;190:1375-82.
70. Leech M, Lacey D, Xue JR et al. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum 2003;48:1881-9.
71. Aupperle KR, Boyle DL, Hendrix M et al. Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. Am J Pathol 1998;152:1091-8.
72. Leech M, Metz C, Bucala R, Morand EF. Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43:827-33.
73. Berdeli A, Mir S, Ozkayin N et al. Association of macrophage migration inhibitory factor -173C allele polymorphism with steroid resistance in children with nephrotic syndrome. Pediatr Nephrol 2005;20:1566-71.
74. De Benedetti F, Meazza C, Vivarelli M et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003;48:1398-407.
75. Aeberli D, Yang Y, Mansell A et al. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett 2006;580:974-81.
76. Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 2005;35:3405-13.
77. Lasa M, Abraham SM, Boucheron C et al. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 2002;22:7802-11.
78. Kassel O, Sancono A, Kratzschmar J et al. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001;20:7108-16.
79. Toh ML, Yang Y, Leech M et al. Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: Up-regulation by interleukin-1beta and glucocorticoids. Arthritis Rheum 2004;50:3118-28.
80. Clark AR, Lasa M. Crosstalk between glucocorticoids and mitogen-activated protein kinase signalling pathways. Curr Opin Pharmacol 2003;3:404-11.
81. Salojin KV, Owusu IB, Millerchip KA et al. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 2006;176:1899-907.
82. Chi H, Barry SP, Roth RJ et al. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci USA 2006;103:2274-9.
83. Han J, Ulevitch RJ. Emerging targets for anti-inflammatory therapy. Nat Cell Biol 1999;1E39-40.
84. Kotlyarov A, Neininger A, Schubert C et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999;1:94-7.
85. Yang H, Wu GS. p53 Transactivates the Phosphatase MKP1 Through Both Intronic and Exonic p53 Responsive Elements. Cancer Biol Ther 2004;3.
86. Karin M. How NF-is activated: The role of the IκB kinase (IKK) complex. Oncogene 1999;18:6867-74.
87. Auphan N, DiDonato JA, Rosette C et al. Immunosuppression by glucocorticoids: Inhibition of NF-activity through induction of Isynthesis. Science 1995;270:286-90.
88. Rea D, van Kooten C, van Meijgaarden KE et al. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood 2000;95:3162-7.
89. Wu JY, Cunha FQ, Liew FY, Weiser WY. IL-10 inhibits the synthesis of migration inhibitory factor and migration inhibitory factor-mediated macrophage activation. J Immunol 1993;151: 4325-32.
90. Stavitsky AB, Xianli J. In vitro and in vivo regulation by macrophage migration inhibitory factor (MIF) of expression of MHC-II, costimulatory, adhesion, receptor, and cytokine molecules. Cell Immunol 2002;217:95-104.
91. McGlone JJ, Lumpkin EA, Norman RL. Adrenocorticotropin stimulates natural killer cell activity. Endocrinology 1991;129:1653-8.
92. Szabo C, Thiemermann C, Wu CC et al. Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. Proc Natl Acad Sci USA 1994;91:271-5.
93. Vacchio MS, Ashwell JD. Thymus-derived glucocorticoids regulate antigen-specific positive selection. J Exp Med 1997;185:2033-8.
94. Gonzalo JA, Gonzalez-Garcia A, Martinez C, Kroemer G. Glucocorticoid-mediated control of the activation and clonal deletion of peripheral T cells in vivo. J Exp Med 1993;177:1239-46.
95. Goulding NJ. The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus. Curr Opin Pharmacol 2004;4:629-36.
96. Barnes PJ. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci 1998;94:557-72.
97. Reichardt HM, Tuckermann JP, Gottlicher M et al. Repression inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. Embo J 2001;20:7168-73.
98. Adcock IM, Lane SJ, Brown CR et al. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med 1995;182:1951-8.
99. Burger-Kentischer A, Goebel H, Seiler R et al. Expression macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 2002;105:1561-6.
100. Burger-Kentischer A, Gobel H, Kleemann R et al. Reduction of the aortic inflammatory response in spontaneous atherosclerosis blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis 2006;184:28-38.
101. Herder C, Kolb H, Koenig W et al. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: Results from the cooperative health research in the region of Augsburg, survey (KORA S4). Diabetes Care 2006;29:368-71.
102. Cvetkovic I, Al-Abed Y, Miljkovic D et al. Critical role macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 2005;146:2942-51.
103. Satoskar AR, Bozza M, Rodriguez Sosa M et al. Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect Immun 2001;69:906-11.
104. Rodriguez-Sosa M, Rosas LE, David JR et al. Macrophage migration inhibitory factor plays a critical role in mediating protection against the helminth parasite Taenia crassiceps. Infect Immun 2003;71:1247-54.
105. Shkolnik T, Livni E, Reshef R et al. Comparison of two lymphokines (macrophage migration inhibition, leukocyte adherence inhibition factors) and carcinoembryonic antigen, in colorectal cancer and colonic premalignant lesions. Am J Gastroenterol 1987;82:1275-8.
106. Shkolnik T, Livni E, Reshef R et al. The macrophage migration inhibition (MIF) assay as a marker of colorectal cancer. Studies patients with colorectal cancer, noncolonic neoplasms, and conditions predisposing to colorectal cancer. Dis Colon Rectum 1987;30:101-5.
107. Wilson JM, Coletta PL, Cuthbert RJ et al. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 2005;129:1485-503.